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Should Large Cell Neuroendocrine Lung Carcinoma be
Classified and Treated as a Small Cell Lung Cancer or with
Other Large Cell Carcinomas?
John M. Varlotto, MD,* Laura Nyshel Medford-Davis, BA,† Abram Recht, MD,†‡
John C. Flickinger, MD,§ Eric Schaefer, MS, Dani S. Zander, MD,¶ and Malcolm M. DeCamp, MD#
Background: To compare the presenting and prognostic characteris-
tics of patients with large cell neuroendocrine lung cancer (LCNELC)
with those of patients with small cell lung cancer (SCLC) or other large
cell carcinomas (OLCs) and to compare overall survival (OS) and lung
cancer-specific survival (LCSS) rates for patients undergoing definitive
resection without radiotherapy (S-NoRT).
Methods: The Surveillance Epidemiology and End Results Data-
base-17 from 2001 to 2007 was used. Differences between popula-
tion characteristics were compared using 2 and Wilcoxon tests. The
log-rank test and Cox models were used to compare differences in
OS and LCSS.
Results: There were 1211 patients with LCNELC (324 in the
S-NoRT group), 8295 patients with OLC (1120 S-NoRT), and
35,304 patients with SCLC (355 S-NoRT). The proportion of all
large cell carcinomas constituted by LCNELC increased from 8 to
21% during the study period; and the proportion of patients with
large cell carcinoma undergoing S-NoRT increased from 16 to 26%.
Presenting and histopathologic characteristics and treatment factors
of patients undergoing S-NoRT for patients with LCNELC were
more similar to those of patients with OLC than to those with SCLC.
OS and LCSS rates for patients with LCNELC undergoing resection
without radiation were similar to those of patients with OLC and
better than those for patients with SCLC, but the differences were
not statistically significant on multivariate analysis.
Conclusions: The clinical, histopathologic, and biologic features of
LCNELC are more similar to OLC than to SCLC. Therefore,
LCNELC should continue to be classified and treated as a large cell
carcinoma.
Key Words: Large cell neuroendocrine carcinoma, Small cell car-
cinoma, Large cell carcinoma, Prognosis, Patient characteristics.
(J Thorac Oncol. 2011;6: 1050–1058)
In 1991, Travis et al.1,2 described a rare but distinct histologiclung cancer, described as having large cell sizes with abundant
cytoplasm, a high mitotic rate, extensive necrosis, and a neu-
roendocrine growth pattern. These large cell neuroendocrine
lung cancers (LCNELCs) shared some histologic features with
small cell lung carcinoma (SCLC), but SCLC consists of smaller
cells with scant cytoplasm, which invades tissues in sheets. The
higher mitotic rates and more extensive necrosis of LCNELC
and SCLC distinguish them from the lower grade neuroendo-
crine tumors, typical and atypical carcinoids. The World Health
Organization (WHO) currently classifies LCNELC as a distinct
subtype of pulmonary large cell carcinoma.3 Diagnosis of
LCNELC hinges on recognition of a neuroendocrine architec-
tural pattern, appropriate cytologic features and mitotic rate, and
confirmation of neuroendocrine differentiation by immunohis-
tochemistry or electron microscopy.4
A previous retrospective report demonstrated that sur-
vival rates of patients with surgically-resected LCNELC and
SCLC were similar to each other and inferior to that of
patients with atypical carcinoid and typical carcinoid tumors.5
The authors concluded that histology-specific sensitivity to
treatment should be clarified. Nevertheless, questions remain
whether LCNELC is best classified and treated as a SCLC or
as a large cell carcinoma. The purposes of our study were,
therefore, to help determine these issues by comparing the
presenting patient and histopathologic characteristics of all
patients with LCNELC with those of patients with SCLC and
other large cell carcinomas (OLCs); and comparing patient,
histopathologic, and treatment factors and lung cancer-spe-
cific survival (LCSS) and overall survival (OS) rates of
patients with LCNELC undergoing surgical resection without
radiation (S-NoRT) with those of patients SCLC and OLC.
PATIENTS AND METHODS
Data were obtained from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program of the US National
Cancer Institute. The SEER-17 database includes patients
diagnosed from 1973 to 2007 and is derived from a set of
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geographically defined, population-based, cancer registries
operated under direct contract by local nonprofit organiza-
tions in Connecticut, Iowa, Hawaii, New Mexico, Utah,
Atlanta, Detroit, Los Angeles, San Francisco-Oakland, San
Jose-Monterey, Seattle-Puget Sound, Rural Georgia, Ken-
tucky, Louisiana, New Jersey, and among Arizona Indians
and Alaskan Native populations.6 The case ascertainment rate
from the SEER registries has been reported to be 97.5% and
is felt to be generally representative of the entire American
population.7 Data on patients diagnosed from 2001 to 2007
were accessed on May 9, 2010. Because we used existing
data which did not identify individual subjects, informed
consent by the study participants was not necessary.
Patients diagnosed with LCNELC, OLC, and SCLC
were selected for analysis by using histology codes in the
database. LCNELC, code 8013; SCLC, code 8041 plus com-
bined small cell (8045) and fusiform cell carcinomas (8043);
and OLC, large cell carcinoma-nos (8012), large cell carci-
noma with rhabdoid phenotype (8014), lymphoepithelioma-
like carcinoma (8082), basaloid carcinoma (8123), and clear
cell carcinoma (8310).
Sociodemographic and clinical factors recorded in-
cluded age; sex; race; marital status; tumor stage; T-stage;
N-stage; M-stage; extension coding (see later); number of
nodes examined (for patients undergoing surgery); number of
nodes positive; pathologic tumor size; tumor location (right
upper, right middle, right lower, left upper, left lower lobe,
mainstem bronchi, lung not otherwise specified, and overlap-
ping lesions); type of resection for patients undergoing de-
finitive surgery (wedge/segmental resection, [bi]lobectomy,
or pneumonectomy); the use of radiation and its sequencing
with surgery; and tumor grade (well differentiated, moder-
ately differentiated, unknown, poorly differentiated, and un-
differentiated). Fewer than 1% of LCNELC, OLC, and SCLC
were classified as grade 1 or 2, and these were excluded from
further analysis due to possible confusion with atypical or
typical carcinoids.
Extension codes used to describe different presenta-
tions of lung cancer were different between the years 2001–
2003 and 2004–2007, resulting in slightly different defini-
tions of central-based lesions during the two time periods.
Codes used from 2001 to 2003 were separate tumor nodules
in the same lobe (65); malignant pleural effusion (72); sep-
arate tumor nodules in a different lobe (77); and metastatic
disease involving the contralateral lung (78). Central-based
lesions included those with extension to the mainstem bron-
chus greater than 2 cm from the carina (20); tumor confined
to the carina (25); tumor involving the mainstem bronchus
less than 2 cm from carina (50); involvement of major blood
vessels, esophagus, mediastinum, carina or trachea (70);
involvement of the heart or visceral pericardium (71); and
malignant pericardial effusion (79). Codes used from 2004 to
2007 included multiple lesions in same lobe (65) and malig-
nant pleural effusion (72). Central lesions were identified as
superficial tumors involving bronchial wall (11); tumors ex-
tending to (20) or involving (21) the mainstem bronchus;
tumor confined to the hilus (23) or carina (25); atelectasis or
obstructive pneumonitis extending to the hilar region (40)
plus tumor involving the mainstem bronchus less than 2 cm
from the carina (52); tumor involving the mainstem bronchus
less than 2 cm from the carina (50) plus extension to visceral
pleura plus tumor (53); atelectasis or obstructive pneumonitis
involving the entire lung (55); involvement of the parietal
pericardium or pericardium, not otherwise specified (56);
involvement of major blood vessels, esophagus, mediastinum
or trachea (70); involvement of the heart or visceral pericar-
dium (71); extension to the aorta (74); invasion of vertebral
body (75); involvement of the inferior vena cava (77); and
malignant pericardial effusion (79). The presence of tumor
nodules in a different ipsilateral lobe (35) was differentiated
from having metastatic disease in the contralateral lung (39).
The proportion of patients with SCLC, OLC, LCNELC,
and NSCLC in the SEER database was compared. Differences
between these proportions and characteristics of these histologic
groups were compared using 2 and Wilcoxon tests.
OS was defined as the time from date of diagnosis until
the date of death. Patients alive at last follow-up were
censored at that time. LCSS was defined as the time from the
date of diagnosis until the date of death due to lung cancer.
Patients alive at last follow-up were censored at that time, and
patients who died due to other causes were censored at the
time of death. Kaplan-Meier curves were constructed for OSS
and LCSS; the log-rank test and Cox models were used to
compare differences between these in different subgroups.
RESULTS
There were 1211 patients with LCNELC (324 in the
S-NoRT group), 8295 patients with OLC (1120 S-NoRT),
and 35,304 patients with SCLC (355 S-NoRT) identified in
the database. LCNELC constituted only 0.4 to 0.6% of all
lung cancers and 0.8 to 1% of lung cancers in patients
undergoing definitive resection during the study period. The
proportion of all large cell carcinomas constituted by
LCNELC increased by 160% during the study period (from 8 to
21%, p  0.01); and the proportion of patients with large cell
carcinoma undergoing S-NoRT increased by 60% (from 16 to
26%, respectively, p  0.01). The proportion of OLC and
LCNELC together as a proportion of all lung cancers slightly
decreased over the years of our study for all patients (from 5 to
3%) and for those undergoing surgery (from 6 to 4%).
Presenting characteristics for all patients presenting with
SCLC, OLC, and LCNELC are described in Table 1. There
were significant differences between patients with LCNELC and
OLC in 7 of 10 categories and between LCNELC and SCLC in
9 of 10 categories. Patients with LCNELC and OLC were more
likely to be male and undergo surgical resection, but less likely
to be non-Hispanic white or present with metastatic disease than
patients with SCLC. Furthermore, patients with either OLC or
LCNELCwere less likely to experience death due to lung cancer
than patients with SCLC. Comparison of these characteristics for
only patients undergoing surgery without radiotherapy is listed
in Table 2. Again, LCNELC was closer to OLC than SCLC,
differing significantly from the former in 3 of 15 categories and
from the latter in 7 of 15 categories. In particular, patients with
SCLC were more likely to be in advanced stages, have a lower
a number of nodes examined, and have a higher lymph node
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No. of patients 1211 8295 35,304
Age 0.01 0.01
Mean (SD) 66.5 (10.85) 67.8 (11.09) 67.5 (10.29)
Median 67.0 69.0 68.0
Range 23.0–85.0 21.0–85.0 20.0–85.0
Sex 0.56 0.01
Female 525 (43.4%) 3522 (42.5%) 17,565 (49.8%)
Male 686 (56.6%) 4773 (57.5%) 17,739 (50.2%)
Race/origin 0.03 0.01
Unknown 2 (0.2%) 8 (0.1%) 44 (0.1%)
White non-Hispanic 964 (79.6%) 6359 (76.7%) 29,749 (84.3%)
White Hispanic 65 (5.4%) 437 (5.3%) 1502 (4.3%)
Black non-Hispanic 113 (9.3%) 1059 (12.8%) 2671 (7.6%)
Black Hispanic 1 (0.1%) 12 (0.1%) 30 (0.1%)
Asian or Pacific Islander 57 (4.7%) 383 (4.6%) 1096 (3.1%)
Other 9 (0.7%) 37 (0.4%) 212 (0.6%)
Marital status 0.59 0.36
Divorced 146 (12.1%) 949 (11.4%) 4564 (12.9%)
Married (including common law) 655 (54.1%) 4452 (53.7%) 18,078 (51.2%)
Separated 10 (0.8%) 88 (1.1%) 363 (1%)
Single (never married) 140 (11.6%) 1029 (12.4%) 4074 (11.5%)
Unknown 38 (3.1%) 204 (2.5%) 1050 (3%)
Widowed 222 (18.3%) 1573 (19%) 7175 (20.3%)
Stage 0.01 0.01
Unknown 110 (9.1%) 1037 (12.5%) 4017 (11.4%)
Stage I 220 (18.2%) 784 (9.5%) 902 (2.6%)
Stage II 80 (6.6%) 343 (4.1%) 518 (1.5%)
Stage III 292 (24.1%) 2337 (28.2%) 9467 (26.8%)
Stage IV 509 (42%) 3794 (45.7%) 20,400 (57.8%)
Surgery 0.01 0.01
Unknown 0 (0%) 5 (0.1%) 11 (0%)
No surgery 765 (63.2%) 6580 (79.3%) 34,415 (97.5%)
Definitive surgery 445 (36.7%) 1683 (20.3%) 815 (2.3%)
Local tumor destruction 1 (0.1%) 27 (0.3%) 63 (0.2%)
Primary radiation 0.01 0.01
Unknown 43 (3.6%) 299 (3.6%) 1165 (3.3%)
No 913 (75.4%) 5153 (62.1%) 21,169 (60%)
Yes 255 (21.1%) 2843 (34.3%) 12,970 (36.7%)
Radiation sequence 0.01 0.01
No (neo)adjuvant radiation 1006 (83.1%) 7458 (89.9%) 33,269 (94.2%)
Radiation before surgery 26 (2.1%) 131 (1.6%) 79 (0.2%)
Radiation after surgery 164 (13.5%) 657 (7.9%) 1848 (5.2%)
Radiation before and after surgery 4 (0.3%) 14 (0.2%) 14 (0%)
Other 11 (0.9%) 35 (0.4%) 94 (0.3%)
Extent 0.01 0.01
Central lesion 211 (17.4%) 1344 (16.2%) 7640 (21.6%)
Malignant pleural effusion 92 (7.6%) 940 (11.3%) 5484 (15.5%)
Separate nodules in different lobes 24 (2%) 191 (2.3%) 628 (1.8%)
Contralateral lung 33 (2.7%) 371 (4.5%) 946 (2.7%)
Multiple lesions in same lobe 43 (3.6%) 247 (3.0%) 1282 (3.7%)
All other presentations 808 (66.7%) 5202 (62.7%) 19,325 (54.7%)
Cause of death
No. of deaths 829 6657 29,585
Lung and bronchus 698 (84.2%) 5653 (84.9%) 25,984 (87.8%) 0.20 0.03
Second cancer 58 (7%) 361 (5.4%) 1525 (5.2%)
Cardiovascular 22 (2.7%) 244 (3.7%) 711 (2.4%)
Pulmonary 12 (1.4%) 113 (1.7%) 346 (1.2%)
Other 39 (4.7%) 286 (4.3%) 1019 (3.4%)
LCNELC, large cell neuroendocrine lung cancer; LCSS, lung cancer-specific survival; OLC, other large cell carcinomas; SCLC, small cell lung cancer.
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No. of patients 324 1120 355
Age 0.13 0.01
Mean (SD) 67.0 (10.15) 67.8 (10.24) 69.3 (9.23)
Median 68.0 69.0 70.0
Range 35.0–85.0 27.0–85.0 24.0–85.0
Sex 0.37 0.08
Female 145 (44.8%) 470 (42%) 183 (51.5%)
Male 179 (55.2%) 650 (58%) 172 (48.5%)
Race/origin 0.45 0.19
Unknown 1 (0.3%) 0 (0%) 0 (0%)
White non-Hispanic 264 (81.5%) 922 (82.3%) 314 (88.5%)
White Hispanic 13 (4%) 56 (5%) 10 (2.8%)
Black non-Hispanic 28 (8.6%) 82 (7.3%) 20 (5.6%)
Asian or Pacific Islander 17 (5.2%) 55 (4.9%) 10 (2.8%)
Other 1 (0.3%) 5 (0.4%) 1 (0.3%)
Marital status 0.54 0.07
Divorced 38 (11.7%) 113 (10.1%) 34 (9.6%)
Married (including common law) 190 (58.6%) 667 (59.6%) 182 (51.3%)
Separated 0 (0%) 10 (0.9%) 3 (0.8%)
Single (never married) 34 (10.5%) 112 (10%) 41 (11.5%)
Unknown 9 (2.8%) 25 (2.2%) 18 (5.1%)
Widowed 53 (16.4%) 193 (17.2%) 77 (21.7%)
Stage 0.15 0.03
Unknown 26 (8%) 110 (9.8%) 43 (12.1%)
Stage I 186 (57.4%) 566 (50.5%) 169 (47.6%)
Stage II 53 (16.4%) 193 (17.2%) 56 (15.8%)
Stage III 59 (18.2%) 251 (22.4%) 87 (24.5%)
Extent 0.08 0.12
Central lesion 30 (9.3%) 132 (11.8%) 40 (11.3%)
Malignant pleural effusion 2 (0.6%) 19 (1.7%) 7 (2%)
Separate tumor nodules in different lobe 0 (0%) 13 (1.2%) 4 (1.1%)
Tumor nodules in same lobe 17 (5.3%) 39 (3.5%) 16 (4.5%)
Other 275 (84.9%) 917 (81.9%) 288 (81.1%)
No. of nodes examined
n 276 976 309 0.57 0.01
Mean (SD) 7.7 (8.00) 7.9 (8.08) 6.4 (7.42)
Median 6.0 6.0 4.0
Range 0.0–55.0 0.0–90.0 0.0–37.0
Positive nodes
n 317 1091 339 0.61 0.59
Mean (SD) 0.7 (1.68) 0.8 (2.05) 0.8 (1.80)
Median 0.0 0.0 0.0
Range 0.0–15.0 0.0–28.0 0.0–12.0
N stage
NX 0 (0%) 7 (0.6%) 2 (0.6%) 0.72 0.15
NO 224 (69.1%) 749 (66.9%) 216 (60.8%)
N1 55 (17%) 215 (19.2%) 67 (18.9%)
N2 39 (12%) 126 (11.3%) 57 (16.1%)
N3 0 (0%) 2 (0.2%) 10 (2.8%)
Lymph nodes, NOS; unknown 4 (1.2%) 15 (1.3%) 3 (0.8%)
Regional nodes, NOS 2 (0.6%) 6 (0.5%) 0 (0%)
(Continued)
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ratio (number of nodes positive to number of nodes examined)
than patients with LCNELC or OLC.
The median follow-up was 6 months for the total
population and 15 months for those undergoing surgery;
median follow-up for patients still living was 13 and 24
months, respectively. One, 2, and 4-year OS rates by histo-
logic type for patients undergoing surgery without radiother-
apy are reported in Table 3 and shown graphically in Figure 1.
On univariate Cox modeling, the hazard ratio (HR) for OS
was 1.32 comparing SCLC and LCNELC (p  0.01) but was
0.97 comparing OLC and LCNELC (p 0.73). Nevertheless,
multivariate Cox analysis (which included age, sex race,
marital status, stage, the number of nodes examined, the
number of nodes positive, tumor location, tumor grade, type
of surgical resection, and central-based tumor as well as
histology) showed no significant differences in OS between
TABLE 3. Overall Survival and Lung Cancer-Specific
Survival in Relationship to Histology for Patients Undergoing
Surgery without Radiotherapy
Histologic Group 1 yr (%) 2 yr (%) 4 yr (%)
OS
LCNELC 76 56 41
OLC 76 60 42
SCLC 69 49 32
LCSS
LCNELC 82 64 57
OLC 82 68 54
SCLC 74 56 42
LCNELC, large cell neuroendocrine lung cancer; LCSS, lung cancer-specific survival;








n 319 1081 325 0.01 0.01
Mean (SD) 31.9 (18.06) 38.3 (24.72) 29.1 (51.11)
Median 27.0 32.0 23.0
Range 3.0–95.0 1.0–250.0 5.0–900.0
Location
Right lower lobe 56 (17.3%) 172 (15.4%) 55 (15.5%) 0.25 0.21
Right middle lobe 14 (4.3%) 61 (5.4%) 22 (6.2%)
Right upper lobe 104 (32.1%) 377 (33.7%) 104 (29.3%)
Right main bronchus 1 (0.3%) 3 (0.3%) 2 (0.6%)
Left lower lobe 56 (17.3%) 158 (14.1%) 49 (13.8%)
Left upper lobe 89 (27.5%) 297 (26.5%) 109 (30.7%)
Left main bronchus 0 (0%) 9 (0.8%) 3 (0.8%)
Lung, NOS 1 (0.3%) 18 (1.6%) 7 (2%)
Overlapping lesions 3 (0.9%) 23 (2.1%) 4 (1.1%)
Other 0 (0%) 2 (0.2%) 0 (0%)
Lymph node ratio
n 235 840 234 0.87 0.02
Mean (SD) 0.1 (0.21) 0.1 (0.22) 0.2 (0.32)
Median 0.0 0.0 0.0
Range 0.0–1.0 0.0–1.0 0.0–1.0
Type of surgery
Sublobar excision 71 (21.9%) 189 (16.9%) 117 (33%) 0.01 0.01
(bi)Lobectomy 235 (72.5%) 813 (72.6%) 224 (63.1%)
Pneumonectomy 18 (5.6%) 118 (10.5%) 14 (3.9%)
Grade
Unknown 108 (33.3%) 154 (13.8%) 122 (34.4%) 0.01 0.01
Poorly differentiated; grade III 163 (50.3%) 428 (38.2%) 111 (31.3%)
Undifferentiated; anaplastic; grade IV 53 (16.4%) 538 (48%) 122 (34.4%)
Cause of death
No. of deaths 129 476 185
Lung and bronchus 93 (72.1%) 347 (72.9%) 146 (78.9%) 0.95 0.38
Second cancer 9 (7%) 28 (5.9%) 6 (3.2%)
Cardiovascular 8 (6.2%) 35 (7.4%) 6 (3.2%)
Pulmonary 6 (4.7%) 17 (3.6%) 9 (4.9%)
Other 13 (10.1%) 49 (10.3%) 18 (9.7%)
LCNELC, large cell neuroendocrine lung cancer; LCSS, lung cancer-specific survival; NOS, not otherwise specificed; OLC, other large cell carcinomas; SCLC, small cell lung cancer.
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SCLC and LCNELC (HR: 1.09, p  0.50) or between OLC
and LCNELC (HR: 0.82, p  0.09). Variables significantly
associated with OS were increasing age (HR: 1.32 per 10-year
increase, p  0.0001); male gender (HR: 1.38, p  0.0002);
stage II (HR: 1.83, p  0.0001) and stage III (HR: 2.26, p 
0.0001) compared with stage I; increasing number of positive
nodes (HR: 1.81 per 1 node increase p 0.002); and increasing
tumor size (HR: 1.03 per 1 cm increase, p  0.001).
One, 2, and 4-year LCSS rates by histologic type for
patients undergoing surgery without radiotherapy are reported in
Table 3 and shown graphically in Figure 2. Univariate Cox
analysis for LCSS in patients undergoing resection without
radiotherapy demonstrated significant differences between
SCLC and LCNELC (HR: 1.46, p  0.005) but not between
OLC and LCNELC (HR: 0.98, p  0.87). Nevertheless, multi-
variate Cox analysis again demonstrated no significant differ-
ences between SCLC and LCNELC (HR: 1.20, p  0.24) and
between OLC and LCNELC (HR: 0.86, p  0.24). Variables
significantly associated with LCSS included increasing age (HR:
1.27 per 10-year increase, p 0.0001); male gender (HR: 1.38,
p 0.002), stage II (HR: 2.30, p 0.0001), stage III (HR: 2.99,
p 0.0001), or unknown stage (HR: 1.73, p 0.003) compared
with stage I disease; increasing number of nodes examined (HR:
0.82 per 1 node increase, p  0.02); increasing number of
positive nodes (HR: 1.92 per 1 node increase, p  0.001); and
increasing tumor size (HR: 1.04 per 1-cm increase, p 0.0001).
To examine whether histology impacted outcome for
patients with very early-stage cancers, we examined rates of
OS and LCSS for patients with pathologic T1N0 tumors
undergoing lobectomy or bilobectomy without radiotherapy.
These results are listed in Table 4 and Figures 3 and 4.
Univariate Cox analysis for OS revealed significantly lower
survival for SCLC compared with LCNELC (HR: 1.67, p 
0.0569) and no difference between OLC and LCNELC (HR:
1.05, p  0.8339). Nevertheless, multivariate Cox analysis
demonstrated no significant differences between SCLC and
LCNELC (HR: 1.42, p  0.24) or between OLC and
LCNELC (HR: 0.85, p  0.55). Increasing age was the only
variable significantly associated with OS (HR: 1.36 per 10-year
increase, p 0.01). Univariate Cox analysis for LCSS revealed
a nonsignificant trend for a difference between SCLC and
LCNELC (HR: 1.68, p 0.13) but no difference between OLC
and LCNELC (HR: 1.06, p  0.85). The only factor approach-
ing significance for LCSS in multivariate analysis was increas-
ing age (HR: 1.28 per 10-year increase, p  0.07).
DISCUSSION
LCNELC is rare, constituting 1% or fewer of lung
cancers and an even smaller proportion of patients undergo-
FIGURE 1. Overall survival by histology for patients who
received definitive surgery without radiation.
FIGURE 2. Lung cancer-specific survival by histology for
patients who received definitive surgery without radiation.
TABLE 4. Overall Survival and Lung Cancer-Specific
Survival in Relationship to Histology for Patients Undergoing
Surgery without Radiotherapy, Tumor Size Smaller Than 3
cm with Uninvolved Lymph Nodes (pT1N0)
Histologic Group 1 yr (%) 2 yr (%) 4 yr (%)
OS
LCNELC 90 76 60
OLC 87 74 57
SCLC 80 62 37
LCSS
LCNELC 93 83 73
OLC 93 81 73
SCLC 86 75 62
LCNELC, large cell neuroendocrine lung cancer; LCSS, lung cancer-specific
survival; OLC, other lung cancer; OS, overall survival; SCLC, small cell lung cancer.
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ing resection in the SEER-17 database. The diagnosis of
LCNELC requires performing either immunohistochemical
staining or electron microscopy to identify neuroendocrine
differentiation, and the detection of key diagnostic architec-
tural characteristics and mitotic rate can be difficult, partic-
ularly when only a small biopsy or cytology specimen is
obtained.8,9 The overwhelming majority of patients in the
SEER database did not undergo definitive surgery, and hence,
the proportion of patients with LCNELC may be underesti-
mated. In series from specialist institutions, LCNELC com-
prised 2 to 3.5% of diagnoses among surgically-treated pa-
tients.10–14 The proportion of LCNELC increased over time
in our study, both in relationship to the total number of all
large cell carcinomas and to the number of patients with large
cell carcinoma undergoing surgery. The reason for this rising
incidence is unknown, but we speculate that it may be due to
increased recognition of LCNELC by pathologists, leading to
reclassification of tumors that otherwise would have been
interpreted to be poorly differentiated non-small cell lung
cancers9 or generic large cell carcinomas without clear signs
of glandular or squamous differentiation.15 Distinguishing
LCNELC from SCLC can occasionally be difficult because of
overlap in cell and nuclear size,16 and it is possible that a
number of cases currently classified as LCNELC could have
been previously included in the SCLC category. Such mis-
classification could potentially mask differences in presenting
characteristics and outcome between LCNELC and SCLC.
Patients with LCNELC had characteristics and OS and
LCSS rates that were more similar to those of patients with OLC
than SCLC. Nevertheless, although both OS and LCSS were
significantly higher for patients with LCNELC and OLC under-
going resection without radiation therapy than for those with
SCLC on univariate analysis, this was not true on multivariate
analysis, whether for the entire population of patients treated
surgically or for patients with pT1N0 tumors undergoing lobec-
tomy or bilobectomy. Nevertheless, the SEER database does not
record the use of chemotherapy, and therefore, we cannot assess
the impact it may have had on outcome. It seems likely that
patients with resected SCLC were more likely to receive che-
motherapy than patients with LCNELC or OLC as there has
been considerable skepticism about the benefits of chemother-
apy in patients with resected NSCLC (especially in T1N0
cases),17–21 compared with its routine use in all patients with
SCLC. Also, because the average ages of patients in both
surgical groups were 66 to 70 years, and because patients
presenting with all three histologic types would be expected to
have other smoking-induced comorbidities,22,23 treating physi-
cians may have been even less likely to give chemotherapy to
patients with LCNELC or OLC.24 Nevertheless, despite the
probable likelihood of a higher use of chemotherapy in patients
with resected T1NO SCLC, the differences between SCLC and
LCNELC or OLC in LCSS and OS in this population and in the
larger surgical group were similar, suggesting that these differ-
ences in OS and LCSS may reflect true biologic differences. We
hypothesize that the higher use of chemotherapy in the patients
with SCLC would only dampen the LCSS and OS differences
between SCLC and OLC as well as LCNEC. Although there are
variables which are not included in the SEER database that
could have affected patient outcome, such as performance status,
weight loss, and the completeness of resection, there is no reason
that such variables would have been unbalanced between the
three histologic groups, and any potential difference would only
decrease the differences among the histologies. Nevertheless, we
still found that OS and LCSS rates as well as presenting, patient,
and pathologic characteristics of LCNELC more closely resem-
ble OLC than SCLC. We feel that LCNELC should continue to
FIGURE 3. Overall survival by histology for patients who
received lobectomy or bilobectomy without radiation for
pathologic T1N0 tumors.
FIGURE 4. Lung cancer-specific survival by histology for
patients who received lobectomy or bilobectomy without
radiation for pathologic T1N0 tumors.
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be classified and treated as a large cell carcinoma rather than a
small cell carcinoma. We encourage future studies to clarify the
histology-specific sensitivity to treatment to further evaluate
potential differences between the three histologies.
Although it may be difficult to be dogmatic regarding
treatment considerations for LCNELC, we feel that because
LCNELC and OLC share many clinical and pathologic char-
acteristics in addition to having a similar prognosis when
compared with SCLC that these differences may represent
biologic differences similar to the higher likelihood of mu-
tated EGFR to be associated nonsmokers, females, Asian
ancestry, and adenocarcinomas.25 As compared with SCLC,
LCNELC and OLC were more likely to be associated with
lower stage disease, male sex, higher number of nodes ex-
amined, and a lower lymph node ratio (number of nodes
positive/number of nodes examined), but less likely to non-
Hispanic white and to have central-based tumors.
The SEER-17 program is beneficial for evaluating a
rare diagnosis such as LCNELC because this database con-
tains approximately 26% of the US population. Because of
the rarity of this diagnosis, most investigations are repre-
sented by relatively small, retrospective, single-institution
studies.10–14 Because of the fact that NSCLC classification
with surgical samples has fair reproducibility between pathol-
ogists when compared with small biopsies,26 we analyzed
surgical patients separately. Nevertheless, similar to our find-
ings with the total population, we demonstrated that the
presenting and prognostic characteristics of surgically-re-
sected patients with LCNEC were still more similar to pa-
tients with OLC than patients with SCLC. Furthermore,
because the SEER-17 database contains such a large cross-
section of patients with lung cancer in the United States, we
feel that our results may be more representative of one
diagnosed with LCNEC than single institution experiences.
Unfortunately, there are limitations to SEER, including lack
of information concerning performance status, weight loss,
patient smoking status, lymphatic and/or vascular invasion,
completeness of resection, lymph node level dissected, pre-
operative evaluation, receipt of chemotherapy, type of che-
motherapeutic agents, and recurrence pattern. Furthermore,
our analysis was limited to the years 2001–2007 because
SEER did not contain information regarding LCNEC in any
other years. The SEER-17 centers use the WHO Pathologic
Classification, and this database only includes LCNELC after
WHO officially recognized this entity in 1999. Although a
pathology review was not able to be obtained, a past inde-
pendent review of SEER data revealed reasonable reliability
of the lung cancer histologic types.27 Similarly, as LCNELC,
OLC, and SCLC are classified as poorly differentiated sub-
types of lung cancer, we found it reassuring that less than 1%
of such tumors were classified as grade 1 or 2.
Finally, we recognize that large cell carcinomas can be
a heterogeneous group. Nevertheless, currently, there are no
guidelines that any of the specific types should be treated or
classified differently, so we felt that we could lump these
diverse histologies under OLC; 95.1% of the OLC group was
represented by large cell carcinoma, not otherwise specified.
The other 4.9% were proportioned as follows: large cell
carcinoma with rhabdoid phenotype (0.1%), lymphoepitheli-
oma (0.2%), basaloid carcinoma (0.3%), and clear cell car-
cinoma (4.3%).
CONCLUSIONS
The clinical, histopathologic, and biologic features of
LCNELC are more similar to OLC than to SCLC. Hence,
LCNELC should continue to be classified and treated as a
large cell carcinoma.
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